- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Chemotherapy Induced Peripheral Neuropathy Treatment market will register a 6.7% CAGR in terms of revenue, the global market size will reach $ 2011.4 million by 2025, from $ 1549.3 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Chemotherapy Induced Peripheral Neuropathy Treatment business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Peripheral Neuropathy Treatment market by type, application, key manufacturers and key regions and countries.
This study considers the Chemotherapy Induced Peripheral Neuropathy Treatment value and volume generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Platinum Agents
Taxanes
Vinca Alkaloids
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Aptinyx Inc
Immune Pharmaceuticals Inc
Asahi Kasei Pharma Corp
MAKScientific LLC
Metys Pharmaceuticals AG
Regenacy Pharmaceuticals
Sova Pharmaceuticals Inc
Nemus Bioscience Inc
DermaXon LLC
PledPharma
Solasia Pharma K.K.
Kineta Inc
Apexian Pharma
PeriphaGen
WinSanTor
Krenitsky Pharmaceuticals Inc
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Chemotherapy Induced Peripheral Neuropathy Treatment consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Chemotherapy Induced Peripheral Neuropathy Treatment market by identifying its various subsegments.
Focuses on the key global Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Chemotherapy Induced Peripheral Neuropathy Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Chemotherapy Induced Peripheral Neuropathy Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption 2015-2025
2.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption CAGR by Region
2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Type
2.2.1 Calcium Channel α2-delta Ligands
2.2.2 Antidepressants
2.2.3 Opioids
2.2.4 Others
2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Type (2015-2020)
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue and Market Share by Type (2015-2020)
2.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Type (2015-2020)
2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Segment by Application
2.4.1 Platinum Agents
2.4.2 Taxanes
2.4.3 Vinca Alkaloids
2.4.4 Others
2.5 Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
2.5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Market Share by Type (2015-2020)
2.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Value and Market Share by Type (2015-2020)
2.5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Type (2015-2020)
3 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company
3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company
3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Company (2018-2020)
3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Company (2018-2020)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company
3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Company (2018-2020)
3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Company (2018-2020)
3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sale Price by Company
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Chemotherapy Induced Peripheral Neuropathy Treatment by Regions
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment by Regions
4.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
4.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
4.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Growth
5 Americas
5.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries
5.1.1 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2015-2020)
5.1.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2015-2020)
5.2 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
5.3 Americas Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Regions
6.1.1 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Regions (2015-2020)
6.1.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Value by Regions (2015-2020)
6.2 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
6.3 APAC Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2015-2020)
7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2015-2020)
7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment by Countries
8.1.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Value by Countries (2015-2020)
8.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Type
8.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
10.3 Chemotherapy Induced Peripheral Neuropathy Treatment Customer
11 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast
11.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Consumption Forecast (2021-2025)
11.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Regions
11.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Regions (2021-2025)
11.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Type
11.8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast by Application
12 Key Players Analysis
12.1 Aptinyx Inc
12.1.1 Company Information
12.1.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Aptinyx Inc Latest Developments
12.2 Immune Pharmaceuticals Inc
12.2.1 Company Information
12.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.2.3 Immune Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Immune Pharmaceuticals Inc Latest Developments
12.3 Asahi Kasei Pharma Corp
12.3.1 Company Information
12.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.3.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Asahi Kasei Pharma Corp Latest Developments
12.4 MAKScientific LLC
12.4.1 Company Information
12.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 MAKScientific LLC Latest Developments
12.5 Metys Pharmaceuticals AG
12.5.1 Company Information
12.5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Metys Pharmaceuticals AG Latest Developments
12.6 Regenacy Pharmaceuticals
12.6.1 Company Information
12.6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.6.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Regenacy Pharmaceuticals Latest Developments
12.7 Sova Pharmaceuticals Inc
12.7.1 Company Information
12.7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.7.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Sova Pharmaceuticals Inc Latest Developments
12.8 Nemus Bioscience Inc
12.8.1 Company Information
12.8.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.8.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Nemus Bioscience Inc Latest Developments
12.9 DermaXon LLC
12.9.1 Company Information
12.9.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 DermaXon LLC Latest Developments
12.10 PledPharma
12.10.1 Company Information
12.10.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.10.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 PledPharma Latest Developments
12.11 Solasia Pharma K.K.
12.11.1 Company Information
12.11.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.11.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Solasia Pharma K.K. Latest Developments
12.12 Kineta Inc
12.12.1 Company Information
12.12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.12.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Kineta Inc Latest Developments
12.13 Apexian Pharma
12.13.1 Company Information
12.13.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Apexian Pharma Latest Developments
12.14 PeriphaGen
12.14.1 Company Information
12.14.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.14.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 PeriphaGen Latest Developments
12.15 WinSanTor
12.15.1 Company Information
12.15.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.15.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.15.4 Main Business Overview
12.15.5 WinSanTor Latest Developments
12.16 Krenitsky Pharmaceuticals Inc
12.16.1 Company Information
12.16.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Offered
12.16.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2018-2020)
12.16.4 Main Business Overview
12.16.5 Krenitsky Pharmaceuticals Inc Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Chemotherapy Induced Peripheral Neuropathy Treatment Consumption CAGR by Region 2015-2025 ($ Millions)
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
